Shares of Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) rose sharply in today's pre-market trading after the company announced it will report on December 18 interim data from its Phase 1 clinical trial evaluating Soquelitinib in patients with moderate to severe atopic dermatitis.
Corvus Pharmaceuticals shares jumped 22.5% to $9.06 in the pre-market trading session.
Here are some other stocks moving in pre-market trading.
Gainers
Losers
Now Read This:
© 2026 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
To add Benzinga News as your preferred source on Google, click here.
